All News
Biologics Do Not Increase Melanoma Risk
Rheumatoid arthritis (RA) patients have a higher risk of certain cancers (e.g., skin, lung, lymphoma). At issue is whether the newer agents modify this risk appreciably.
Read ArticleSteroids, DMARDs and Biologics have Same Low Risk of Infection During Pregnancy
Low rates of serious infections were observed in pregnant women receiving immunosuppressive therapies. Higher rates may be seen with steroid use in pregnancy and SIE trend towards lowest with DMARD or TNFi use.
Read ArticleThe RheumNow Week in Review – 24 March 2017
Dr. Jack Cush reviews news and highlights from the past week on RheumNow.com.
Read ArticleSjogren's Syndrome Foundation's 2017 Sjogren's Treatment Guidelines
Dr. Steven Carsons and an expert committee of the Sjogren's Syndrome Foundation have published a clinical practice guidelines (CPGs) and recommendations for the managment of Sjögren's syndrome.
Read ArticleCheckpoint Inhibitors Causing Rheumatic Disease
Calabrese and Velcheti have reviewed the current understanding that underlies a new drug-induced rheumatic disease - checkpoint inhibitor arthritis and autoimmune disease.
Read ArticleThe RheumNow Week in Review – 17 March 2017
Dr. Jack Cush reviews highlights in the news from the past week at RheumNow.com. News on hepatitis C in RA and risk of hepatotoxicity; TNF inhibitor persistence in PsA; unnecessary injections in pre-operative OA knee patients; and a delay in the FDA decision on abaloparatide.
Read ArticleThe RheumNow Week in Review – 10 March 2017
Dr. Jack Cush reviews news and highlights from the past week on RheumNow.com. Sign up at RheumNow.com to received daily or weekly news, blogs and tweets on all things rheumatology
Read ArticleEuropean Biologic Manufacturers Issue Warnings About Biosimilar Switching
Reuters has reported that European drugmakers have taken the tact of warning EU physician contemplating the switch from existing (originator) biologic therapy to newer, cut-rate biosimilar. Biosimilar use is widespread outside the USA.
Read ArticleEULAR Recommendations on Reproductive Issues in Lupus and Anti-Phospholipid Syndrome
There is a significant unmet need with regard to counseling and managing SLE and APS patients who become pregnant or who may be planning for pregnancy.
Read ArticleHigh Level Rheumatoid Responses to the GM-CSF inhibitor Mavrilimumab
Despite recent advances in treatment of rheumatoid arthritis (RA), MANY patients on existent biological therapy fail to achieve remission. Therapies with novel mechanisms of actions, great efficacy and well balanced safety profile remain an unmet need.
Read ArticleSirukumab Effective in Rheumatoid Arthritis
Sirukumab is a human monoclonal antibody that selectively binds to the interleukin-6 (IL-6) and is being developed for use in rheumatoid arthritis (RA) and other inflammatory diseases.
Read ArticleAbatacept Efficacy Giant Cell Arteritis
This appears to be the year for biologic treatments in giant cell artertis (GCA).
Read ArticleBiosimilar Reports – February 2017
Biosimilar reports is an ongoing series dedicated to advances, discussions and developments in biosimilar agents intended for use by rheumatologists. Many of these items were compiled from news sources, journal articles and regulatory documents and are cited and linked within each section.
Read ArticleThe RheumNow Week in Review – 17 February 2017
Dr. Jack Cush reviews this week's news and information from the 2017 RWCS meeting in Maui.
Read ArticleBEAM Study: Baricitinib Beats Placebo and Adalimumab in Rheumatoid Arthritis
Baricitinib is a novel inhibitor of Janus kinases JAK1 and JAK2 that has been extensively studied in rheumatoid arthritis (RA). Baricitinib (AKA Oluminant) was recently approved by the EMA for use in Europe at a once daily dose of 4 mg per day.
Read ArticleBaricitinib Approved in the EU for Use in Rheumatoid Arthritis
The European Commission has approved Eli Lilly's rheumatoid arthritis drug Olumiant (baricitinib) for use in Europe for RA patients with moderate-to-severe active disease in adults who have not responded one or more disease-modifying antirheumatic drugs.
Read ArticleAn Integrated Analysis of Tofacitinib Safety
Since its US approval in 2012, tofacitinib has become a widely used treatment for rheumatoid arthritis (RA).
Whether you're impressed with its efficacy, or distressed with its side effects, its track record is voluminous and has been recently reviewed.
Read ArticleNovel Peripheral Helper T Cells in RA
US and UK researchers have identified a unique subset of helper T-cells called ‘peripheral helper’ T-cells in the synoviums that may be linked to the pathogenesis of rheumatoid arthritis.
Read ArticleNo Increase in Infections with Pre-Op Infliximab Before Hip or Knee Replacement
Up to 30% of patients with rheumatoid arthritis (RA) will eventually undergo joint reconstructive surgery, yet we have limited data to guide the perioperative management of DMARDs and biologics.
Read ArticleThe RheumNow Week in Review – 3 February 2017
Dr. Jack Cush reviews this week's highlights from RheumNow.
Read Article